Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study

Fig. 3

Change in disease activity based on DAS28-CRP and DAS28-ESR. a DAS28-CRP and b DAS28-ESR adjusted mean change from baseline in the ITT population. c Proportion of patients with remission (DAS28 ≤2.6) or low disease activity (DAS28 ≤3.2) at week 24 in the ITT population. Error bars represent standard error. CRP C-reactive protein, DAS28 disease activity score of 28 joints, ESR erythrocyte sedimentation rate, ITT intention-to-treat

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us